-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Myelofibrosis Drug Details: IMG-7289 is under development for the treatment of acute...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Pertussis (Whooping Cough) – Drugs In Development, 2023
Global Markets Direct’s, ‘Pertussis (Whooping Cough) - Drugs In Development, 2023’, provides an overview of the Pertussis (Whooping Cough) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hand, Foot and Mouth Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Hand, Foot and Mouth Disease - Drugs In Development, 2023’, provides an overview of the Hand, Foot and Mouth Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Neisseria meningitidis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Neisseria meningitidis Infections - Drugs In Development, 2023’, provides an overview of the Neisseria meningitidis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Lyme Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Lyme Disease - Drugs In Development, 2023’, provides an overview of the Lyme Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Poliomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Poliomyelitis - Drugs In Development, 2023’, provides an overview of the Poliomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – anti-KRAS G12D mTCR PBL in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - anti-KRAS G12D mTCR PBL in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Anti-Kras G12D Mtcr Pbl in Prostate Cancer Drug Details:Gene therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Poliomyelitis [Sabin] (Vero Cell) Vaccine in Poliomyelitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Poliomyelitis [Sabin] (Vero Cell) Vaccine in Poliomyelitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poliomyelitis [Sabin] (Vero Cell) Vaccine in Poliomyelitis Drug...
-
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...